Abstract
GlaxoSmithKline will acquire Sitari Pharmaceuticals for an undisclosed sum. GSK and venture capital firm Avalon Ventures founded Sitari in 2013. GSK and Avalon struck a deal at the time to fund up to 10 biotech start-ups at Avalon’s incubator, COI Pharmaceuticals, and have launched 8 start-ups so far. Sitari has focused on developing small-molecule inhibitors of transglutaminase 2, an enzyme that ignites inflammation in response to gluten in people with celiac disease.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
